Studies have reported that inhibitors for epigenetic modifications, such as DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDACi) and EZH2 inhibitors (EZH2i), could reactivate ERα expression in basal-like breast cancer [57–59]. The gene discussed is ESR1; the disease is breast carcinoma.